Medtronic plc stock edges lower as MiniMed exchange offer reshapes portfolio

Medtronic plc stock (ISIN IE00BTN1Y115) recently closed at about USD 92.13 on the NYSE on September 20, 2026, down 0.69% from the prior session as investors weighed its ongoing exchange offer involving MiniMed Group.

MiniMed exchange offer becomes the near term driver

According to MSN on September 20, 2026, Medtronic has launched an exchange offer that will allow its shareholders to tender ordinary shares of Medtronic in return for MiniMed Group common stock at a 7% discount to the MiniMed share price, subject to a maximum of 4.5939 MiniMed shares per Medtronic share accepted.

As MSN reports, if the upper limit does not apply, Medtronic shareholders are expected to receive approximately USD 107.53 worth of MiniMed stock for every USD 100 of Medtronic ordinary shares tendered, effectively giving investors a 7% economic incentive to participate in the transaction.

MiniMed completed its IPO in March 2026, and Medtronic currently owns around 252.8 million MiniMed shares, representing about 90% of the outstanding common stock, with the exchange offer structured to split off at least 80.1% of MiniMed and significantly reduce Medtronic’s stake in the diabetes business according to MSN.

Stock price, range and recent fundamentals

Per recent price data for Medtronic’s NYSE listing, the shares closed at about USD 92.13 on September 20, 2026, compared with an intraday trading range of roughly USD 92.04 to USD 93.03 on that date, leaving the stock modestly lower by 0.64 points, or 0.69% versus the previous close.

The same dataset indicates a market capitalization in the tens of billions of USD for Medtronic as of September 20, 2026, with trading volume in the latest session consistent with normal liquidity levels for a large-cap medical technology company.

For fundamental context, Medtronic reported its fourth-quarter and full-year fiscal 2026 results with what was described as the strongest annual revenue growth in a decade, led by its cardiac portfolio, according to Trillionaire Daily on September 20, 2026.

As Trillionaire Daily reports, Medtronic’s fiscal 2026 revenue approached around USD 32.3 billion, implying that the group’s top line has increased meaningfully compared with prior years and underlining the company’s scale in global medical technology markets.

This combination of a sizable revenue base and the decision to separate the diabetes-focused MiniMed business via the exchange offer means Medtronic is actively reshaping its portfolio while still highlighting growth in core areas such as cardiac devices.

Analyst view and competitive positioning

In terms of relative performance, Medtronic appears to stand out versus at least one peer in the electrophysiology segment. According to Zacks, Medtronic’s stock has significantly outperformed Boston Scientific (BSX) over the past three months, and Zacks assigns Medtronic a Rank #3 (Hold) compared with a Rank #5 (Strong Sell) for Boston Scientific.

The same analysis from Zacks suggests that Medtronic may be worth holding at present, while investors in Boston Scientific might consider exiting until operational visibility improves, underscoring the comparatively more favorable stance on Medtronic despite the neutral rank.

Beyond electrophysiology, Medtronic’s broader product portfolio includes mechanical ventilators and respiratory interventions equipment, with its Patient Monitoring and Respiratory Interventions portfolio featuring Puritan Bennett ventilator series such as the PB980 and PB840, which are widely used in high-acuity intensive care settings according to Market Growth Reports.

Stock level and investor perspective

Based on the most recent NYSE data as of September 20, 2026, Medtronic plc stock closed at around USD 92.13, in USD, with the modest single day decline occurring as the market continues to assess the implications of the MiniMed exchange offer and the company’s recent fiscal 2026 revenue performance.

More news and analyses on Medtronic plc stock